Posted by Michael Wonder on 27 Jul 2023
New Brunswick to publicly reimburse Albrioza for the treatment of ALS
24 July 2023 - New Brunswick lists Albrioza on its drug benefit formulary, becoming the fourth province to provide public reimbursement
Amylyx Pharmaceuticals Canada announced today that the Company has entered into a Product Listing Agreement with New Brunswick for the public reimbursement of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) through the New Brunswick public drug plan effective 24 July 2023 for the treatment of amyotrophic lateral sclerosis.
